Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-06-06
1999-06-15
Stanton, Brian R.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
424 931, 424 932, 424 9321, 424 936, 424 937, 4353201, 435440, 435455, 435456, 435458, A01N 4304, A61N 6300, C12N 510, C12N 1509
Patent
active
059122366
ABSTRACT:
The present invention relates to a broad-spectrum tumor suppressor gene and the protein expressed by that gene in appropriate host cells. The protein is a second in-frame AUG codon-initiated retinoblasoma protein of about 94 kD relative molecular mass. The present invention also relates to methods of treating a mammal having a disease or disorder characterized by abnormal cellular proliferation, such as a tumor or cancer and methods of treating abnormally proliferating cells, such as tumor or cancer cells. Treatment is accomplished by inserting a host cell compatible p94.sup.RB expression vector or an effective amount of p94.sup.RB protein into a cell or cells in need of treatment.
REFERENCES:
patent: 4740463 (1988-04-01), Weinberg et al.
patent: 4942123 (1990-07-01), Lee et al.
patent: 5174993 (1992-12-01), Paoletti
Af Trampe et al., 1983, Results Obtained in Treating Retinoblastoma patients with Different Techniques at the Karolinska Hospital, Springer-Verlag pp. 529-533.
Ahlering et al., 1987, A New in Vivo Model to Study Invasion and Metastasis of Human Bladder Carcinoma, Cancer Research 47:6660-6665.
Akiyama et al., 1990, Marked alteration in phosphorylation of the RB protein during differentiation of human promyelocytic HL 60 cells, Oncogene 5:179-183.
Anderson, 1992, Human Gene Therapy, Science 256:808-813.
Ausubel et al., 1992, Short Protocols in Molecular Biology, Current Protocols in Molecular Biology, John Wiley and Jones, New York.
Baker et al., 1990, Suppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53, Science 249:912-915.
Ballester et al, 1990, The NF1 Locus Encodes a Protein Functionally Related to Mammalian GAP and Yeast IRA Proteins, Cell 63:851-859.
Banerjee et al., 1992, Changes in Growth and Tumorigenicity following Reconstitution of Retinoblastoma Gene Function in Various Human Cancer Cell Types by Microcell Transfer of Chromosome 13, Cancer Research 52:6297-6304.
Bayer et al., 1980, The Use of the Avidin-Biotin Complex as a Tool in Molecular Biology, Methods Biochem. Anal. 26:1-45.
Benedict et al.,1990, Role of the Retinoblastoma Gene in the Initiation and Progression of Human Cancer, J. Clin. Invest. 85:988-993.
Benoist et al., 1981, In vivo sequence requirements of the SV40 early promoter region, Nature 290:304-310.
Bookstein et al., 1991, Molecular Genetics of the Retinoblastoma Suppressor Gene, Crit. Rev. Oncog. 2(3):211-227.
Bookstein et al, 1990, Suppression of Tumorigenicity of Human Prostate Carcinoma Cells by Replacing a Mutated RB Gene, Science 247:712-715.
Brinster et al., 1982, Regulation of metallothionein-thymidine kinase fusion plasmids injected into mouse eggs, Nature 296:39-42.2.
Brown et al., 1984, Mechanism of activation of an N-ras gene in the human fibrosarcoma cell line HT1080, EMBO J. 3(6):1321-1326.
Buchkovich et al., 1989, The Retinoblastoma Protein is Phosphorylated during Specific Phases of the Cell Cycle, Cell 58:1097-1105.
Ceccoli et al., 1989, Encapsulation of the UV-DNA Repair Enzyme T4 Endocuclease V in Liposomes and Delivery to Human Cells, Journal of Investigative Dermatology 93:190-194.
Chen et al., 1989, Phosphorylation of the Retinoblastoma Gene Product is Modulated during the Cell Cycle and Cellular Differentiation, Cell 58:1193-1198.
Culver et al., 1992, In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors, Science 256:1550-1552.
Culver et al., 1991, Lymphocyte Gene Therapy, Human Gene Therapy 2:107-109.
Curiel et al., 1991, Adenovirus enhancement of transferrin-polylysine-mediated gene delivery, Proc. Natl. Acad. Sci. USA 88:8850-8854.
Davies, 1992, Moving stright to the target, Nature genetics 358:519.
DeCaprio et al., 1989, The Product of the Retinoblastoma Susceptibility Gene Has Properties of a Cell Cycle Regulatory Element, Cell 58:1085-1095.
Diller et al., 1990, p53 Functions as a Cell Cycle Control Protein in Osteosarcomas, Molecular and Cellular Biology 10(11):5772-5781.
Durst et al., 1987, Papillomavirus sequences integrate near cellular oncogenes in some cervical carcinomas, Proc. Natl. Acad. Sci. USA 84(4):1070-1074.
Fearon et al., 1990, A Genetic Model for Colorectal Tumorigenesis, Cell 61:759-767.
Francois et al., Mar./Apr., The Costenbader Memorial Lecture Genesis and Genetics of Retinoblastoma, Journal of Pediatric Ophthalmology and Strabismus 16(2):85-100.
Friend et al., 1987, Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: Organization of the sequence and its encoded protein, Proc. Natl. Acad. Sci. USA 84:9059-9063.
Furukawa et al., 1990, Expression and state of phosphorylation of the retinoblastoma susceptibility gene product in cycling and noncycling human hematopoietic cells, P.N.A.S. USA 87:2770-2774.
Gallie et al, 1991, The Genetics of Retinoblastoma: Relevance to the Patient, Pediatric Clinics of North America 38(2):299-315.
Gallie et al., 1992, How do Retinoblastoma Tumours Form?, Eye 6:226-231.
Goodrich et al., 1992, Abrogation by c-myc of G1 phase arrest induced by RB protein but not by p53, Nature 360:177-179.
Goodrich et al., 1992, Expression of the Retinoblastoma Gene Product in Bladder carcinoma Cells Associates with a Low Frequency of Tumor Formation, Cancer Research 52:1968-1973.
Gunning et al., 1987, A human .beta.-actin expression vector system directs high-level accumulation of antisense transcripts, Proc. Natl. Acad. Sci. USA 84:4831-4835.
Hamel et al., 1992, Transcriptional Repression of the E2-Containing Promoters EllaE, c-myc, and RB1 by the Product of the RB1 Gene, Molecular and Cellular Biology 12(8):3431-3438.
Huang et al.,1988, Suppression of the Neoplastic Phenotype by Replacement of the RB Gene in Human Cancer Cells, Science reports 242:1563-1566.
Jaffe et al., 1992, Adenovirus-mediated in vivo gene transfer and expression in normal rat liver, Nature genetics 1:372-378.
Karasuyama et al., 1989, Autocrine Growth and Tumorigenicity of Interleukin 2-Dependent Helper T Cells Transfected with IL-2 Gene, J. Exp. Med. 169:13.
Klessig et al., 1984, Introduction, Stable Integration, and Controlled Expression of a Chimeric Adenoirus Gene Whose Product Is Toxic to the Recipient Human Cell, Mol. Cell Biol. 4:1354-1362.
Knight et al., 1988, Antiviral Therapy with Small Particle Aerosols, European Journal of Clinical Microbiology and Infectious Diseases 7(6):721-731.
Kratzke et al., 1992,Functional Analysis at the Cys-706 Residue of the Retinoblastoma Protein, The Journal of Biological Chemistry 267(36):25998-26003.
Kutty et al., 1992, Heme oxygenase: expression in human retina and modulation by stress agents in a human retinoblastoma cell model system, Oxford University Press 11(2):153-160.
Lee et al., 1990, Molecular biology of the Human Retinoblastoma Gene, Immunol Ser. 51:169-200.
Lee et al., 1987, The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity, Nature 329:642-645.
Lemarchand et al., 1992, Adenovirus-mediated transfer of a recombinant human alpha.sub.1 -antitrypsin cDNA to human endothelial cells, P.N.A.S. USA 89:6482-6486.
Lin et al., 1992, Nasopharyngeal Carcinoma and Retinoblastoma Gene Expression, Laboratory Investigation 67(1):56-70.
Ludlow et al., 1989, SV40 Large T Antigen Binds Preferentially to an Underphosphorylated Member of the Retinoblastoma Susceptibility Gene Product Family, Cell 56:57-65.
Lynch et al., 1991, Production of High-Titer Helper Virus-Free Retroviral Vectors by Cocultivation of Packaging Cells with Different Host Ranges, J. Virol. 65:3887-3890.
Maniatis et al., 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
Mannino et al., 1988,Liposome Mediated Gene Transfer, Biotechniques 6(7):682-690.
Marshall, 1991, Tumor Suppressor Genes, Cell 64:313-326.
McGee et al., 1989, Structure and partial genomic sequence of the human retinoblastoma susceptibility gene, Gene 80:119-128.
Mihara et al., 1989, Cell Cycle-Dependent regulation of Phosphorylation of the Human Retinoblastoma Gene Product, Science 246:1300-1303.
Miller, 1992, Human gene therapy comes of ag
Benedict William F.
Hu Shi-Xue
Xu Hong-Ji
Baylor College of Medicine
Stanton Brian R.
LandOfFree
Broad-spectrum tumor suppressor genes gene products and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Broad-spectrum tumor suppressor genes gene products and methods , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Broad-spectrum tumor suppressor genes gene products and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-402576